Man Group
IMVT icon

Man Group’s Immunovant IMVT Stock Holding History

Man Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-109,390
Closed -$3.12M – 2080
2024
Q3 		$3.12M Buy
+109,390
New +$3.23M 0.01% 1181
2024
Q2 		– Sell
-75,920
Closed -$2.45M – 2131
2024
Q1 		$2.45M Sell
75,920
-98,237
-56% -$3.58M 0.01% 1233
2023
Q4 		$7.34M Buy
+174,157
New +$6.41M 0.02% 798
2021
Q1 		– Sell
-8,604
Closed -$397K – 1920
2020
Q4 		$397K Buy
+8,604
New +$398K ﹤0.01% 1599

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Man Group's IMVT Position: Q4 2024 in Review

Man Group sold out of Immunovant (IMVT) in Q4 2024, closing a stake of 109,390 shares — an estimated $3.12M sold.

Man Group first reported a position in IMVT in Q4 2020 and held it in 4 quarters. The position peaked at $7.34M in Q4 2023. 186 funds tracked by Wall St. Rank hold IMVT as of Q4 2024.

  • Man Group reported no remaining Immunovant position as of Q4 2024 after selling out during the quarter.
  • Man Group sold 109,390 Immunovant shares in Q4 2024, an estimated $3.12M.
  • Man Group first reported a position in Immunovant in Q4 2020 and held it in 4 quarters.
  • Man Group's Immunovant position peaked at $7.34M in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q4 2024.

Based on Man Group's 13F filing for Q4 2024, filed 14 Feb 2025.